PMID- 30788459
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201208
IS  - 2475-3246 (Electronic)
IS  - 2475-3246 (Linking)
VI  - 4
IP  - 1
DP  - 2018
TI  - Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among 
      Patients with Gastroenteropancreatic Neuroendocrine Tumors.
PG  - 64-71
LID - 10.1089/pancan.2018.0013 [doi]
AB  - Objective: To examine patients with metastatic gastroenteropancreatic 
      neuroendocrine tumors (GEP-NETs) who receive sequential treatment with 
      somatostatin analogs. Materials and Methods: This retrospective chart review 
      examined lanreotide depot/autogel tolerability and efficacy among GEP-NET 
      patients who received lanreotide after octreotide long-acting release (LAR) at 
      Tufts University Medical Center. Information obtained included background patient 
      characteristics, dosing, adverse events (AEs), radiologic response, and 
      biochemical markers. Results: Patients (n = 16; 43-81 years; mean age, 64.25 
      years; 11 female) with nonfunctional, low-grade GEP-NETs receiving octreotide LAR 
      30-60 mg were transitioned to lanreotide because of patient decision (n = 6), 
      disease progression (n = 6), AEs (n = 2), poor tolerance (n = 1), and injection 
      discomfort/pain (n = 1). Lanreotide doses started at 120 mg (n = 13), 90 mg 
      (n = 1), or 60 mg (n = 2); 8 patients received concomitant therapies, mostly 
      liver-directed (radiofrequency ablation/radioembolization). AEs associated with 
      lanreotide experienced by >/=2 patients were fatigue, diarrhea, nausea, 
      hypertension, pancreatic enzyme deficiency, and hyperglycemia. Radiologic 
      treatment responses of the combination of lanreotide with other therapeutic 
      modalities included complete response (n = 1), partial response (n = 5), and 
      stable disease (n = 9). One patient had radiologic progression. Serum serotonin 
      and chromogranin levels decreased, but urinary 5-hydroxyindoleacetic acid levels 
      appeared relatively unchanged. Conclusion: Among post-octreotide GEP-NET 
      patients, including those with disease progression or poor octreotide tolerance, 
      lanreotide alone or with concomitant therapies was well tolerated and associated 
      with radiologic responses.
FAU - Saif, Muhammad Wasif
AU  - Saif MW
AD  - Department of Medical Oncology, Tufts Cancer Center-Tufts Medical Center, Boston, 
      Massachusetts.
FAU - Fu, Julie
AU  - Fu J
AD  - Department of Medical Oncology, Tufts Cancer Center-Tufts Medical Center, Boston, 
      Massachusetts.
FAU - Smith, Melissa H
AU  - Smith MH
AD  - Department of Medical Oncology, Tufts Cancer Center-Tufts Medical Center, Boston, 
      Massachusetts.
FAU - Weinstein, Barbara
AU  - Weinstein B
AD  - Department of Pathology, Tufts Cancer Center-Tufts Medical Center, Boston, 
      Massachusetts.
FAU - Relias, Valerie
AU  - Relias V
AD  - Department of Medical Oncology, Tufts Cancer Center-Tufts Medical Center, Boston, 
      Massachusetts.
FAU - Daly, Kevin P
AU  - Daly KP
AD  - Department of Invasive Radiology, Tufts Cancer Center-Tufts Medical Center, 
      Boston, Massachusetts.
LA  - eng
GR  - UL1 TR001064/TR/NCATS NIH HHS/United States
PT  - Journal Article
DEP - 20181001
PL  - United States
TA  - J Pancreat Cancer
JT  - Journal of pancreatic cancer
JID - 101703452
PMC - PMC6371583
OTO - NOTNLM
OT  - chromogranin
OT  - gastroenteropancreatic neuroendocrine tumors
OT  - lanreotide depot
OT  - octreotide long-acting release
COIS- M.W.S.: speakers' bureau, Ipsen Biopharmaceuticals; research funding, Ipsen 
      Biopharmaceuticals. J.F., M.H.S., B.W., and K.P.D.: nothing to disclose. V.R.: 
      speakers' bureau, AbbVie, Genentech.
EDAT- 2019/02/23 06:00
MHDA- 2019/02/23 06:01
PMCR- 2018/10/01
CRDT- 2019/02/22 06:00
PHST- 2019/02/22 06:00 [entrez]
PHST- 2019/02/23 06:00 [pubmed]
PHST- 2019/02/23 06:01 [medline]
PHST- 2018/10/01 00:00 [pmc-release]
AID - 10.1089/pancan.2018.0013 [pii]
AID - 10.1089/pancan.2018.0013 [doi]
PST - epublish
SO  - J Pancreat Cancer. 2018 Oct 1;4(1):64-71. doi: 10.1089/pancan.2018.0013. 
      eCollection 2018.